Fig. 6.
pAKT is a potential biomarker of acquired BRAF-inhibitor resistance in human NSCLC. (A) CT scans obtained before treatment and upon dabrafenib resistance in a patient with BRAFV600E NSCLC. Arrows indicate a metastatic liver lesion in this patient that was confirmed as BRAFV600E NSCLC and that initially responded and then progressed on continuous dabrafenib therapy. (B) Immunohistochemistry staining for pAKT in pretreatment and acquired resistance biopsies from two BRAFV600E NSCLC patients treated with the BRAF inhibitor dabrafenib. Arrows indicate pAKT+ tumor cells. (Scale bars: 50 μM.)